9.5 C
New York
Thursday, April 18, 2024

UBS Downgrades Impax Laboratories To Sell

Courtesy of Benzinga.

Related IPXL
2 Biotech Stocks Deutsche Bank Just Initiated
FTC Requires Divestitures in Connection With Impax Laboratories Inc.'s Proposed Acquisition of CorePharma, LLC

Analysts at UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) from Neutral to Sell.

Impax Laboratories shares have gained 99.84 percent over the past 52 weeks, while the S&P 500 index has gained 12.45 percent in the same period.

Impax Laboratories’ shares declined 3.04 percent to $49.70 in pre-market trading.

Latest Ratings for IPXL

Date Firm Action From To
Apr 2015 UBS Downgrades Neutral Sell
Apr 2015 Deutsche Bank Initiates Coverage on Hold
Apr 2015 Leerink Swann Maintains Market Perform

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: UBSDowngrades Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,359FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x